生殖尿道癌症的最新情况:ASCO 2023的亮点
Qian Qin1, Hollie Sheffield1, Sean M Taasan1
1Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Journal of hematology & oncology
|November 22, 2023
概括
免疫疗法和向疗法的最新进展为生殖尿路癌症 (GU) 提供了新的希望. ASCO 2023强调了新型药物以及在GU恶性瘤中需要最佳治疗序列的必要性.
科学领域:
- 生殖尿道 (GU) 瘤学
- 癌症治疗方法 癌症治疗方法
- 临床试验的进展.
背景情况:
- 生殖尿路 (GU) 恶性瘤是癌症研究的一个重要领域.
- 近年来,在免疫疗法和针对GU癌症的向治疗方面取得了重大进展.
- 改善的临床结果和扩展的治疗选择正在改变患者护理.
研究的目的:
- 在ASCO 2023年度会议上提出的关于GU恶性瘤的关键临床试验进展的总结.
- 突出新兴的新型治疗药物,可能对GU癌症治疗产生影响.
- 强调治疗策略的不断变化以及优化测序的必要性.
主要方法:
- 在ASCO 2023年度会议上提出的临床试验数据和治疗发展的审查.
- 专注于特定的GU癌症类型,包括前列腺癌,尿路细胞癌和细胞癌.
- 将新兴新型药剂纳入早期开发阶段.
主要成果:
- 在治疗前列腺癌的PARP抑制剂方面取得了重大进展.
- 抗体药物合物和纤维细胞生长因子受体抑制剂在尿道癌的进展.
- HIF2a抑制剂对细胞癌的新兴作用.
- 两种特异性抗体的早期发展,仿真抗原受体T细胞和放射性药物显示出高潜力.
结论:
- 在ASCO 2023会议上展示了GU瘤学的重大治疗进展.
- 新型药物正在扩大各种GU恶性瘤的治疗武器库.
- 优化治疗顺序至关重要,以最大限度地提高患者的结果,随着越来越多的选择.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Vaccines
376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356


